Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins

Artikel i vetenskaplig tidskrift
Författare Lisa M Nilsson
Lydia C. Green
Somsundar Veppil Muralidharan
Dagsu Demir
M. Welin
Joydeep Bhadury
D. T. Logan
B. Walse
Jonas A Nilsson
Publicerad i Cancer Research
Volym 76
Nummer/häfte 8
Sidor 2376-2383
ISSN 0008-5472
Publiceringsår 2016
Publicerad vid Institutionen för kliniska vetenskaper, sektionen för kirurgi och kirurgisk gastroforskning, Avdelningen för kirurgi
Sidor 2376-2383
Språk en
Länkar dx.doi.org/10.1158/0008-5472.can-15...
Ämnesord erythroid-differentiation, erythroleukemia-cells, dimethyl-sulfoxide, histone, vorinostat, lymphoma, inducers, trial
Ämneskategorier Cancer och onkologi

Sammanfattning

Agents that trigger cell differentiation are highly efficacious in treating certain cancers, but such approaches are not generally effective in most malignancies. Compounds such as DMSO and hexamethylene bisacetamide (HMBA) have been used to induce differentiation in experimental systems, but their mechanisms of action and potential range of uses on that basis have not been developed. Here, we show that HMBA, a compound first tested in the oncology clinic over 25 years ago, acts as a selective bromodomain inhibitor. Biochemical and structural studies revealed an affinity of HMBA for the second bromodomain of BET proteins. Accordingly, both HMBA and the prototype BET inhibitor JQ1 induced differentiation of mouse erythroleukemia cells. As expected of a BET inhibitor, HMBA displaced BET proteins from chromatin, caused massive transcriptional changes, and triggered cell-cycle arrest and apoptosis in Myc-induced B-cell lymphoma cells. Furthermore, HMBA exerted anticancer effects in vivo in mouse models of Myc-driven B-cell lymphoma. This study illuminates the function of an early anticancer agent and suggests an intersection with ongoing clinical trials of BET inhibitor, with several implications for predicting patient selection and response rates to this therapy and starting points for generating BD2-selective BET inhibitors. (C) 2016 AACR.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?